熱門資訊> 正文
Embecta获得FDA批准用于2型糖尿病贴片泵
2024-09-03 22:24
- Embecta (NASDAQ:EMBC) has received FDA clearance for its disposable insulin delivery system for the treatment of both type 1 and type 2 diabetes.
- The system includes a tubeless patch pump with a 300-unit insulin reservoir and a locked-down controller with Bluetooth technology.
- Embecta said the 300-unit reservoir design is aimed at accommodating the needs of type 2 diabetics who have higher daily insulin needs, according to a statement.
- Embecta added it is also working on a closed-loop patch pump device that includes an insulin-dosing algorithm.
- Wells Fargo pointed out that Insulet (PODD) recently received FDA clearance for its Omnipod 5 insulin delivery system for type 2 diabetes, while Tandem Diabetes Care (TNDM) expects to submit an application to get its device approved for type 2 diabetes “shortly.”
- The investment bank noted that Insulet’s Omnipod 5 only has a 200-unit reservoir versus Embecta’s 300-unit.
- “This is important because people with type 2 tend to use more insulin,” the bank added.
More on Embecta
- Embecta Corp. (EMBC) Q3 2024 Earnings Call Transcript
- Fundamentals Are The Key For Investors Considering Embecta Stock
- Embecta beats top-line and bottom-line estimates; updates FY24 outlook
- Diabetes device maker Embecta exploring sale - FT
- Seeking Alpha’s Quant Rating on Embecta
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
